PTCT PTC Therapeutics, Inc.

12.75
+0.17  (1%)
Previous Close 12.58
Open 12.90
Price To book 4.28
Market Cap 437.53M
Shares 34,316,000
Volume 613,642
Short Ratio 2.95
Av. Daily Volume 1,268,420

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial to commence in 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting
  2. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  3. Today's Research Reports on Stocks to Watch: Horizon Pharma and PTC Therapeutics
  4. [$$] PTC Expects Net Price of $35,000 Annually Per Patient for Emflaza
  5. New price for muscular dystrophy drug draws criticism
  6. Why PTC Therapeutics Stock Is Sinking Today
  7. This rare disease drug was just given a $35,000-a-year price tag. But it’s unclear whether that’s an improvement
  8. CORRECTED: PTC Therapeutics' DMD drug Emflaza to cost $35,000 a year and launch within the coming weeks
  9. PTC Therapeutics reports 1Q loss
  10. PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
  11. Investor Network: PTC Therapeutics, Inc. to Host Earnings Call
  12. Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy
  13. 5 Stocks with Earnings Acceleration to Buy Now
  14. PTC Therapeutics to Host Conference Call to Discuss First Quarter Financial Results
  15. PTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S.
  16. PTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : April 20, 2017
  17. ETFs with exposure to PTC Therapeutics, Inc. : April 19, 2017
  18. PTC Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTCT-US : April 19, 2017
  19. PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs